CL2008002277A1 - Metodo para tratar un trastorno ocular relacionado con tnf alfa que comprende una molecula de arn interferente que actua en la expresion del arnm de tnfr1 o tace mediante interferencia de arn; molecula de arn interferente; composicion que comprende dicho interferente. - Google Patents
Metodo para tratar un trastorno ocular relacionado con tnf alfa que comprende una molecula de arn interferente que actua en la expresion del arnm de tnfr1 o tace mediante interferencia de arn; molecula de arn interferente; composicion que comprende dicho interferente.Info
- Publication number
- CL2008002277A1 CL2008002277A1 CL2008002277A CL2008002277A CL2008002277A1 CL 2008002277 A1 CL2008002277 A1 CL 2008002277A1 CL 2008002277 A CL2008002277 A CL 2008002277A CL 2008002277 A CL2008002277 A CL 2008002277A CL 2008002277 A1 CL2008002277 A1 CL 2008002277A1
- Authority
- CL
- Chile
- Prior art keywords
- rna molecule
- interfering rna
- tnfr1
- interferer
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Método para tratar un trastorno ocular relacionado con tnf alfa que comprende una molécula de arn interferente que actúa en la expresión del arnm de tnfr1 o tace mediante interferencia de arn; molécula de arn interferente; composición que comprende dicho interferente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95382507P | 2007-08-03 | 2007-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008002277A1 true CL2008002277A1 (es) | 2009-07-17 |
Family
ID=40263006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008002277A CL2008002277A1 (es) | 2007-08-03 | 2008-08-01 | Metodo para tratar un trastorno ocular relacionado con tnf alfa que comprende una molecula de arn interferente que actua en la expresion del arnm de tnfr1 o tace mediante interferencia de arn; molecula de arn interferente; composicion que comprende dicho interferente. |
Country Status (6)
Country | Link |
---|---|
US (8) | US20090036396A1 (es) |
AR (1) | AR071146A1 (es) |
CL (1) | CL2008002277A1 (es) |
TW (1) | TW200916117A (es) |
UY (1) | UY31267A1 (es) |
WO (2) | WO2009020847A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200808360A (en) | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
WO2009020847A2 (en) | 2007-08-03 | 2009-02-12 | Alcon Research, Ltd. | Rnai-related inhibition of tnfa signaling pathway for treatment of ocular angiogenesis |
BR112013002767B1 (pt) | 2010-08-05 | 2021-09-14 | B. Braun Melsungen Ag | Conjunto de agulha e método para montar um conjunto de agulha |
WO2014174834A1 (ja) * | 2013-04-25 | 2014-10-30 | 国立大学法人山口大学 | 神経疾患治療剤 |
CN104498498A (zh) * | 2014-12-25 | 2015-04-08 | 广州市锐博生物科技有限公司 | 抑制ADAM17基因的siRNA及其应用 |
CN107904239B (zh) * | 2014-12-25 | 2020-11-27 | 广州市锐博生物科技有限公司 | 抑制ADAMTS-5基因的siRNA及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6531128B1 (en) * | 2000-02-08 | 2003-03-11 | Pharmacia Corporation | Methods for treating glaucoma |
AU2001237939A1 (en) * | 2000-02-08 | 2001-08-20 | Gulgun Tezel | Methods for treating glaucoma |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
WO2003070897A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP3882725B2 (ja) * | 2002-03-12 | 2007-02-21 | 株式会社デンソー | 車両用回転電機 |
JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
WO2005076998A2 (en) * | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Rnai therapeutics for treatment of eye neovascularization diseases |
US8084599B2 (en) * | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
CN101052717A (zh) * | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
ES2413804T3 (es) * | 2006-05-19 | 2013-07-17 | Alcon Research, Ltd. | Inhibición mediada por ARNi de estados relacionados con factor de necrosis tumoral-alfa |
WO2009020847A2 (en) | 2007-08-03 | 2009-02-12 | Alcon Research, Ltd. | Rnai-related inhibition of tnfa signaling pathway for treatment of ocular angiogenesis |
-
2008
- 2008-08-01 WO PCT/US2008/071885 patent/WO2009020847A2/en active Application Filing
- 2008-08-01 TW TW97129263A patent/TW200916117A/zh unknown
- 2008-08-01 UY UY31267A patent/UY31267A1/es not_active Application Discontinuation
- 2008-08-01 CL CL2008002277A patent/CL2008002277A1/es unknown
- 2008-08-01 AR ARP080103367 patent/AR071146A1/es unknown
- 2008-08-01 US US12/184,351 patent/US20090036396A1/en not_active Abandoned
- 2008-08-04 WO PCT/US2008/072061 patent/WO2009020894A2/en active Application Filing
- 2008-08-04 US US12/185,182 patent/US20090036397A1/en not_active Abandoned
-
2010
- 2010-06-29 US US12/825,552 patent/US20100267811A1/en not_active Abandoned
-
2011
- 2011-02-21 US US13/031,358 patent/US20110190376A1/en not_active Abandoned
- 2011-06-27 US US13/169,549 patent/US8754202B2/en active Active
-
2014
- 2014-05-05 US US14/270,197 patent/US9139834B2/en active Active
-
2015
- 2015-08-17 US US14/827,418 patent/US9422556B2/en active Active
-
2016
- 2016-07-25 US US15/218,180 patent/US20160326533A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8754202B2 (en) | 2014-06-17 |
UY31267A1 (es) | 2009-01-05 |
US9422556B2 (en) | 2016-08-23 |
US20110190376A1 (en) | 2011-08-04 |
AR071146A1 (es) | 2010-06-02 |
US20110257248A1 (en) | 2011-10-20 |
TW200916117A (en) | 2009-04-16 |
US20140357696A1 (en) | 2014-12-04 |
US9139834B2 (en) | 2015-09-22 |
US20100267811A1 (en) | 2010-10-21 |
WO2009020847A2 (en) | 2009-02-12 |
WO2009020894A2 (en) | 2009-02-12 |
US20150344886A1 (en) | 2015-12-03 |
WO2009020847A3 (en) | 2009-07-23 |
WO2009020894A3 (en) | 2009-08-27 |
US20160326533A1 (en) | 2016-11-10 |
US20090036397A1 (en) | 2009-02-05 |
US20090036396A1 (en) | 2009-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002401A1 (es) | Anticuerpos contra icos | |
CL2008002277A1 (es) | Metodo para tratar un trastorno ocular relacionado con tnf alfa que comprende una molecula de arn interferente que actua en la expresion del arnm de tnfr1 o tace mediante interferencia de arn; molecula de arn interferente; composicion que comprende dicho interferente. | |
BR112018004620A2 (pt) | moduladores da expressão de kras | |
CO6220968A2 (es) | Inhibidores heterociclicos de la aspartil proteasa | |
CL2016002262A1 (es) | Composiciones y métodos para modular la expresión de ttr y vhb | |
ES2563777T3 (es) | Compuestos de nitrona para tratar la pérdida auditiva sensorineural | |
RS54456B1 (en) | TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA | |
MX2015013096A (es) | Viscosificador para fluidos de pozos de petroleo. | |
CY1112595T1 (el) | Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met | |
ES2421442T3 (es) | Métodos para repeler artrópodos utilizando isolongifolenona | |
MA31564B1 (fr) | Inhibition par arni de l'expression du canal alpha-enac | |
ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
BRPI0709769B8 (pt) | implantes biodegradáveis para o tratamento de estados associados à dopamina | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
CO2020006453A2 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
CL2019002232S1 (es) | Automóvil. | |
CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
CR20200631A (es) | Modulares de la expresión de apol1 | |
CL2021001246A1 (es) | Moduladores de expresión irf5. | |
AR112231A1 (es) | Composición para medio óptico | |
CO2020008769A2 (es) | Moduladores de la expresión dnm2 | |
PE20200749A1 (es) | Moduladores de la expresion de enac | |
CL2019001469S1 (es) | Cepillo de dientes. | |
BR112018011367A2 (pt) | composição de fluidos para tratamento de poços |